Detection of antibodies against botulinum toxins
Identifieur interne :
000A75 ( PascalFrancis/Curation );
précédent :
000A74;
suivant :
000A76
Detection of antibodies against botulinum toxins
Auteurs : Dorothea Sesardic [
Royaume-Uni] ;
Russell G. A. Jones [
Royaume-Uni] ;
Tong Leung [
Royaume-Uni] ;
Toni Alsop [
Royaume-Uni] ;
Robert Tierney [
Royaume-Uni]
Source :
-
Movement disorders [ 0885-3185 ] ; 2004.
RBID : Pascal:04-0228587
Descripteurs français
English descriptors
Abstract
After immunisation with botulinum vaccine, antibodies to multiple epitopes are produced. Only some of these will have the capacity to neutralise the toxin activity. In fact, the ability of toxoid vaccine to induce toxin neutralising antibodies has provided the basis for the use of therapeutic antitoxins and immunoglobulins for the prophylaxis and treatment of diseases caused by bacterial toxins. Increasing indications for the chronic use of botulinum toxin for therapy have inevitably resulted in concern for patients becoming unresponsive because of the presence of circulating toxin-specific antibodies. Highly sensitive and relevant assays to detect only clinically relevant toxin neutralising antibodies are essential. Although immunoassays often provide the sensitivity, their relevance and specificity is often questioned. The mouse protection LD50 bioassay is considered most relevant but can often only detect 10 mIU/ml of antitoxin. This sensitivity, although sufficient for confirming protective immunity, is inadequate for patients undergoing toxin therapy. An intramuscular paralysis assay improves the sensitivity to ca. 1 mIU/ml, and a mouse ex vivo diaphragm assay, with sensitivity of <0.5 mIU/ml, is the most sensitive functional assay to date for this purpose. Alternative approaches for the detection of antibodies to botulinum toxin have included in vitro endopeptidase activity neutralisation. Unlike any other functional assay, this approach is not reliant on serotype-specific antibodies for specificity. Most recent promising developments are focused on cellular assays utilising primary rat embryonic cord cells or more conveniently in vitro differentiated established cell lines such as human neuroblastoma cells.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 19 |
|---|
| A06 | | | | @3 SUP8 |
|---|
| A08 | 01 | 1 | ENG | @1 Detection of antibodies against botulinum toxins |
|---|
| A09 | 01 | 1 | ENG | @1 Basic and Therapeutic Aspects of Neurotoxins |
|---|
| A11 | 01 | 1 | | @1 SESARDIC (Dorothea) |
|---|
| A11 | 02 | 1 | | @1 JONES (Russell G. A.) |
|---|
| A11 | 03 | 1 | | @1 LEUNG (Tong) |
|---|
| A11 | 04 | 1 | | @1 ALSOP (Toni) |
|---|
| A11 | 05 | 1 | | @1 TIERNEY (Robert) |
|---|
| A12 | 01 | 1 | | @1 BIGALKE (HANS) @9 ed. |
|---|
| A12 | 02 | 1 | | @1 DRESSLER (Dirk) @9 ed. |
|---|
| A12 | 03 | 1 | | @1 JANKOVIC (Joseph) @9 ed. |
|---|
| A14 | 01 | | | @1 Division of Bacteriology, National Institute for Biological Standards and Control @2 Potters Bar, Hertfordshire @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. |
|---|
| A15 | 01 | | | @1 Institute of Toxicology, Medical School of Hannover @2 Hannover @3 DEU @Z 1 aut. |
|---|
| A15 | 02 | | | @1 Department of Neurology, Rostock University @2 Rostock @3 DEU @Z 2 aut. |
|---|
| A15 | 03 | | | @1 Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 3 aut. |
|---|
| A20 | | | | @1 85-91 |
|---|
| A21 | | | | @1 2004 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000113591720120 |
|---|
| A44 | | | | @0 0000 @1 © 2004 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 66 ref. |
|---|
| A47 | 01 | 1 | | @0 04-0228587 |
|---|
| A60 | | | | @1 P @2 C |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C01 | 01 | | ENG | @0 After immunisation with botulinum vaccine, antibodies to multiple epitopes are produced. Only some of these will have the capacity to neutralise the toxin activity. In fact, the ability of toxoid vaccine to induce toxin neutralising antibodies has provided the basis for the use of therapeutic antitoxins and immunoglobulins for the prophylaxis and treatment of diseases caused by bacterial toxins. Increasing indications for the chronic use of botulinum toxin for therapy have inevitably resulted in concern for patients becoming unresponsive because of the presence of circulating toxin-specific antibodies. Highly sensitive and relevant assays to detect only clinically relevant toxin neutralising antibodies are essential. Although immunoassays often provide the sensitivity, their relevance and specificity is often questioned. The mouse protection LD50 bioassay is considered most relevant but can often only detect 10 mIU/ml of antitoxin. This sensitivity, although sufficient for confirming protective immunity, is inadequate for patients undergoing toxin therapy. An intramuscular paralysis assay improves the sensitivity to ca. 1 mIU/ml, and a mouse ex vivo diaphragm assay, with sensitivity of <0.5 mIU/ml, is the most sensitive functional assay to date for this purpose. Alternative approaches for the detection of antibodies to botulinum toxin have included in vitro endopeptidase activity neutralisation. Unlike any other functional assay, this approach is not reliant on serotype-specific antibodies for specificity. Most recent promising developments are focused on cellular assays utilising primary rat embryonic cord cells or more conveniently in vitro differentiated established cell lines such as human neuroblastoma cells. |
|---|
| C02 | 01 | X | | @0 002B17 |
|---|
| C03 | 01 | X | FRE | @0 Système nerveux pathologie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Nervous system diseases @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Sistema nervioso patología @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Dépistage @5 02 |
|---|
| C03 | 02 | X | ENG | @0 Medical screening @5 02 |
|---|
| C03 | 02 | X | SPA | @0 Descubrimiento @5 02 |
|---|
| C03 | 03 | X | FRE | @0 Bontoxilysin @2 FE @2 FR @5 03 |
|---|
| C03 | 03 | X | ENG | @0 Bontoxilysin @2 FE @2 FR @5 03 |
|---|
| C03 | 03 | X | SPA | @0 Bontoxilysin @2 FE @2 FR @5 03 |
|---|
| C07 | 01 | X | FRE | @0 Metalloendopeptidases @2 FE |
|---|
| C07 | 01 | X | ENG | @0 Metalloendopeptidases @2 FE |
|---|
| C07 | 01 | X | SPA | @0 Metalloendopeptidases @2 FE |
|---|
| C07 | 02 | X | FRE | @0 Peptidases @2 FE |
|---|
| C07 | 02 | X | ENG | @0 Peptidases @2 FE |
|---|
| C07 | 02 | X | SPA | @0 Peptidases @2 FE |
|---|
| C07 | 03 | X | FRE | @0 Hydrolases @2 FE |
|---|
| C07 | 03 | X | ENG | @0 Hydrolases @2 FE |
|---|
| C07 | 03 | X | SPA | @0 Hydrolases @2 FE |
|---|
| C07 | 04 | X | FRE | @0 Enzyme @2 FE |
|---|
| C07 | 04 | X | ENG | @0 Enzyme @2 FE |
|---|
| C07 | 04 | X | SPA | @0 Enzima @2 FE |
|---|
| N21 | | | | @1 145 |
|---|
| N82 | | | | @1 OTO |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 Toxins 2002. Conference @3 Hannover DEU @4 2002 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002246
Links to Exploration step
Pascal:04-0228587
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Detection of antibodies against botulinum toxins</title>
<author><name sortKey="Sesardic, Dorothea" sort="Sesardic, Dorothea" uniqKey="Sesardic D" first="Dorothea" last="Sesardic">Dorothea Sesardic</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><author><name sortKey="Jones, Russell G A" sort="Jones, Russell G A" uniqKey="Jones R" first="Russell G. A." last="Jones">Russell G. A. Jones</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><author><name sortKey="Leung, Tong" sort="Leung, Tong" uniqKey="Leung T" first="Tong" last="Leung">Tong Leung</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><author><name sortKey="Alsop, Toni" sort="Alsop, Toni" uniqKey="Alsop T" first="Toni" last="Alsop">Toni Alsop</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><author><name sortKey="Tierney, Robert" sort="Tierney, Robert" uniqKey="Tierney R" first="Robert" last="Tierney">Robert Tierney</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0228587</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0228587 INIST</idno>
<idno type="RBID">Pascal:04-0228587</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002246</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000A75</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Detection of antibodies against botulinum toxins</title>
<author><name sortKey="Sesardic, Dorothea" sort="Sesardic, Dorothea" uniqKey="Sesardic D" first="Dorothea" last="Sesardic">Dorothea Sesardic</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><author><name sortKey="Jones, Russell G A" sort="Jones, Russell G A" uniqKey="Jones R" first="Russell G. A." last="Jones">Russell G. A. Jones</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><author><name sortKey="Leung, Tong" sort="Leung, Tong" uniqKey="Leung T" first="Tong" last="Leung">Tong Leung</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><author><name sortKey="Alsop, Toni" sort="Alsop, Toni" uniqKey="Alsop T" first="Toni" last="Alsop">Toni Alsop</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><author><name sortKey="Tierney, Robert" sort="Tierney, Robert" uniqKey="Tierney R" first="Robert" last="Tierney">Robert Tierney</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14><country>Royaume-Uni</country>
</affiliation><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004">2004</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Medical screening</term>
<term>Nervous system diseases</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Dépistage</term>
<term>Bontoxilysin</term>
</keywords><front><div type="abstract" xml:lang="en">After immunisation with botulinum vaccine, antibodies to multiple epitopes are produced. Only some of these will have the capacity to neutralise the toxin activity. In fact, the ability of toxoid vaccine to induce toxin neutralising antibodies has provided the basis for the use of therapeutic antitoxins and immunoglobulins for the prophylaxis and treatment of diseases caused by bacterial toxins. Increasing indications for the chronic use of botulinum toxin for therapy have inevitably resulted in concern for patients becoming unresponsive because of the presence of circulating toxin-specific antibodies. Highly sensitive and relevant assays to detect only clinically relevant toxin neutralising antibodies are essential. Although immunoassays often provide the sensitivity, their relevance and specificity is often questioned. The mouse protection LD<sub>50</sub>
bioassay is considered most relevant but can often only detect 10 mIU/ml of antitoxin. This sensitivity, although sufficient for confirming protective immunity, is inadequate for patients undergoing toxin therapy. An intramuscular paralysis assay improves the sensitivity to ca. 1 mIU/ml, and a mouse ex vivo diaphragm assay, with sensitivity of <0.5 mIU/ml, is the most sensitive functional assay to date for this purpose. Alternative approaches for the detection of antibodies to botulinum toxin have included in vitro endopeptidase activity neutralisation. Unlike any other functional assay, this approach is not reliant on serotype-specific antibodies for specificity. Most recent promising developments are focused on cellular assays utilising primary rat embryonic cord cells or more conveniently in vitro differentiated established cell lines such as human neuroblastoma cells.</div><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA06><s3>SUP8</s3>
</fA06><fA08 i1="01" i2="1" l="ENG"><s1>Detection of antibodies against botulinum toxins</s1>
</fA08><fA09 i1="01" i2="1" l="ENG"><s1>Basic and Therapeutic Aspects of Neurotoxins</s1>
</fA09><fA11 i1="01" i2="1"><s1>SESARDIC (Dorothea)</s1>
</fA11><fA11 i1="02" i2="1"><s1>JONES (Russell G. A.)</s1>
</fA11><fA11 i1="03" i2="1"><s1>LEUNG (Tong)</s1>
</fA11><fA11 i1="04" i2="1"><s1>ALSOP (Toni)</s1>
</fA11><fA11 i1="05" i2="1"><s1>TIERNEY (Robert)</s1>
</fA11><fA12 i1="01" i2="1"><s1>BIGALKE (HANS)</s1>
<s9>ed.</s9>
</fA12><fA12 i1="02" i2="1"><s1>DRESSLER (Dirk)</s1>
<s9>ed.</s9>
</fA12><fA12 i1="03" i2="1"><s1>JANKOVIC (Joseph)</s1>
<s9>ed.</s9>
</fA12><fA14 i1="01"><s1>Division of Bacteriology, National Institute for Biological Standards and Control</s1>
<s2>Potters Bar, Hertfordshire</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14><fA15 i1="01"><s1>Institute of Toxicology, Medical School of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA15><fA15 i1="02"><s1>Department of Neurology, Rostock University</s1>
<s2>Rostock</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA15><fA15 i1="03"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA15><fA20><s1>85-91</s1>
</fA20><fA21><s1>2004</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113591720120</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>66 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>04-0228587</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
</fA60><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC01 i1="01" l="ENG"><s0>After immunisation with botulinum vaccine, antibodies to multiple epitopes are produced. Only some of these will have the capacity to neutralise the toxin activity. In fact, the ability of toxoid vaccine to induce toxin neutralising antibodies has provided the basis for the use of therapeutic antitoxins and immunoglobulins for the prophylaxis and treatment of diseases caused by bacterial toxins. Increasing indications for the chronic use of botulinum toxin for therapy have inevitably resulted in concern for patients becoming unresponsive because of the presence of circulating toxin-specific antibodies. Highly sensitive and relevant assays to detect only clinically relevant toxin neutralising antibodies are essential. Although immunoassays often provide the sensitivity, their relevance and specificity is often questioned. The mouse protection LD<sub>50</sub>
bioassay is considered most relevant but can often only detect 10 mIU/ml of antitoxin. This sensitivity, although sufficient for confirming protective immunity, is inadequate for patients undergoing toxin therapy. An intramuscular paralysis assay improves the sensitivity to ca. 1 mIU/ml, and a mouse ex vivo diaphragm assay, with sensitivity of <0.5 mIU/ml, is the most sensitive functional assay to date for this purpose. Alternative approaches for the detection of antibodies to botulinum toxin have included in vitro endopeptidase activity neutralisation. Unlike any other functional assay, this approach is not reliant on serotype-specific antibodies for specificity. Most recent promising developments are focused on cellular assays utilising primary rat embryonic cord cells or more conveniently in vitro differentiated established cell lines such as human neuroblastoma cells.</s0><fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Dépistage</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Medical screening</s0>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Descubrimiento</s0>
<s5>02</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03><fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07><fN21><s1>145</s1>
</fN21><fN82><s1>OTO</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>Toxins 2002. Conference</s1>
<s3>Hannover DEU</s3>
<s4>2002</s4>
</fA30>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000A75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:04-0228587
|texte= Detection of antibodies against botulinum toxins
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
